HCA Healthcare, Inc.

HCA Healthcare, Inc. (HCA) Market Cap

HCA Healthcare, Inc. has a market capitalization of $80.16B.

Price: $361.32

-10.81 (-2.90%)

Market Cap: 80.16B

NYSE · time unavailable

CEO: Samuel N. Hazen

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2011-03-10

Website: https://www.hcahealthcare.com

HCA Healthcare, Inc. (HCA) - Company Information

Market Cap: 80.16B|Sector: Healthcare

Company Profile

HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Analyst Sentiment

80%
Strong Buy

From 46 Active Polls

1Y Forecast: $504.73

▲ +39.7% Potential Upside

Consensus Target Metrics

Low Bound

$413

Median

$520

High Bound

$635

Average

$505

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$504.73
▲ +39.69% Upside
Low Target
$413.00
14% Risk
Median Target
$520.00
44% Mid
High Target
$635.00
76% Max
Consensus
Buy
30 / 46 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)80,155107,261107,709103,33692,67686,19475,728105,63882,945
Enterprise Value ($M)129,060156,166156,867148,688138,101131,570119,032147,639124,888
Price to Earnings Ratio (P/E)12.0516.5514.3415.7214.0213.3813.1720.7914.19
Price/Earnings-to-Growth Ratio (PEG)7.815.269.0467.982.8916.08
Price to Sales Ratio (P/S)1.055.615.525.394.984.704.146.044.74
Price to Book Ratio (P/B)-12.99-17.02-17.87-19.37-21.09-24.49-30.30-48.41-51.84
Price to Free Cash Flow Ratio (P/FCF)10.11119.84123.8033.0430.55130.6059.4445.46120.21
Enterprise Value to Sales (EV/Sales)8.178.047.767.427.186.518.447.14
Enterprise Value to EBITDA (EV/EBITDA)8.2441.1737.7538.4435.9135.2433.8445.2535.06
Debt to Equity Ratio3.12-7.91-8.33-8.69-10.55-13.20-18.10-20.57-26.73

HCA Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$361.32
Intrinsic Value$298.05
Market Alignment
Overvalued by 17.5%relative to calculated intrinsic value
9.00%
Exp: 7%7%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$10.96B
Perpetuity TV Value$206.25B
Discounted TV (PV)$87.12B
TV Weighting %61.3%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HCA HEALTHCARE INC (HCA) — Investment Overview

🧩 Business Model Overview

HCA operates a portfolio of acute-care hospitals and affiliated outpatient facilities. Revenue is generated when patients receive inpatient and outpatient clinical services, with reimbursement driven primarily by payer mix (commercial insurers, Medicare, and Medicaid) and negotiated payment rates. The company also benefits from provider network integration through employed physicians, hospital-based specialty services, and referral patterns that support care continuity across settings (emergency, inpatient, and outpatient).

Operationally, HCA’s “value chain” is: (1) secure and maintain clinical capacity and service lines in defined service areas, (2) manage patient flow through emergency and referral sources, (3) deliver care with cost discipline (labor, supplies, and facility utilization), and (4) contract with payers to align reimbursement with care delivery. Patient demand is relatively recurring; demand variability is mitigated by broad service coverage and physician/community referral relationships.

💰 Revenue Streams & Monetisation Model

Monetisation is largely transactional but exhibits stability due to the recurring nature of acute care. Revenue drivers include:

  • Inpatient services: Surgical and medical admissions, with revenue influenced by case mix and acuity.
  • Outpatient services: Emergency department visits and a growing set of outpatient procedures and specialty services.
  • Ancillary services: Imaging, labs, pharmacy, and other hospital-based services that often attach to broader episodes of care.
  • Payer reimbursement structure: Reimbursement is driven by negotiated commercial rates, Medicare payment rules, and Medicaid program specifics (which vary by state).

Primary margin drivers typically include: (1) labor productivity and staffing model effectiveness, (2) occupancy/utilization and throughput, (3) supply chain and procurement leverage, (4) payor contracting outcomes and mix of insured patients, and (5) the mix of higher-acuity inpatient services and profitable outpatient growth relative to cost structure.

🧠 Competitive Advantages & Market Positioning

HCA’s moat is best characterized as a combination of scale-driven cost advantages, regulatory and capital barriers, and integrated care delivery that reinforces referral and continuity. While healthcare demand is not “switchable” in the same way software platforms are, patients and referring clinicians still face meaningful practical friction when switching hospitals—especially for specialty services, physician alignment, and established care pathways.

Key moat elements

  • High barriers to entry (regulatory + capital intensity): Building and operating acute-care capacity requires substantial capital, extensive clinical staffing, and regulatory approvals that can be difficult to replicate quickly.
  • Operational scale and purchasing leverage: Large volume supports procurement efficiency and standardized operating practices across facilities.
  • Provider alignment and referral stickiness: Employed physicians and specialty coverage can strengthen referral capture in the service areas HCA serves.
  • Integrated ecosystem across care settings: Emergency-to-inpatient-to-outpatient pathways support revenue capture across episodes and can reduce leakage versus purely single-site operators.

Competitive benchmarking

  • Universal Health Services (UHS): UHS is a major healthcare services operator with a significant focus on behavioral health and acute-care segments. Compared with UHS, HCA’s positioning is more heavily weighted toward large acute-care hospital networks with extensive general and specialty services.
  • Tenet Healthcare (THC): Tenet also operates acute-care hospitals and outpatient facilities in competitive markets. HCA’s scale across a broader footprint can enhance purchasing leverage and operational standardization relative to smaller or more regionally concentrated peers.
  • Community Health Systems (CYH): CYH focuses on community hospitals, often with different market dynamics and operational execution constraints. HCA’s network breadth and associated integration across service lines typically provide greater ability to manage fixed-cost structures and optimize case mix.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular healthcare utilization trends and capacity/portfolio development:

  • Demographics and demand for acute services: Aging populations increase utilization of inpatient and outpatient clinical services, including chronic disease management episodes that flow into acute care.
  • Shift toward outpatient and facility-based care: Migration from inpatient settings to outpatient procedures and ambulatory services can support revenue growth if paired with disciplined cost control.
  • Service line depth and specialty care expansion: Expanding specialty programs and higher-acuity service offerings can improve case mix and strengthen referral capture.
  • Capacity augmentation and geographic portfolio optimization: Select facility expansions, new campuses, and upgrades can address local demand while maintaining economies of scale.
  • Value-based and payer contracting evolution: Contracting models that reward quality, outcomes, and utilization management can support longer-run pricing stability if HCA’s operational systems reduce avoidable utilization.

⚠ Risk Factors to Monitor

  • Regulatory reimbursement pressure: Changes to Medicare/Medicaid payment models, wage index rules, or site-of-service reimbursement can compress margins.
  • Payer mix and contracting dynamics: Greater commercial reimbursement pressure or unfavorable contract renewals can affect net revenue per case.
  • Labor costs and staffing constraints: Healthcare delivery is labor-intensive; sustained labor cost inflation or staffing shortages can impair operating margins.
  • High capital intensity and leverage: Continued facility upgrades, technology investments, and interest expense exposure can impact free cash flow and financial flexibility.
  • Utilization and acuity volatility: Patient volumes and case mix can fluctuate with economic conditions and public health events.
  • Legal, compliance, and cybersecurity risks: Hospitals face substantial compliance obligations and increasing cybersecurity exposure that can lead to direct costs and reputational damage.

📊 Valuation & Market View

Hospital operators are typically valued on earnings power and cash generation, with the market often focusing on EV/EBITDA and earnings-based multiples and the quality of operating margins and free cash flow. Key valuation sensitivities include:

  • Operating margin trajectory: Labor productivity, supply chain discipline, and utilization/occupancy are central.
  • Reimbursement outlook: Expected changes in Medicare/Medicaid and commercial contract terms influence sustainable net revenue.
  • Capital allocation and leverage: The pace of capex and debt structure affects financial resilience through reimbursement and labor cycles.
  • Portfolio mix: Service line mix (higher acuity, specialty depth, outpatient contribution) can influence both growth and margin durability.

In general, the market assigns value to operators with credible execution on cost discipline, consistent reimbursement outcomes, and manageable leverage through the reimbursement and labor cycle.

🔍 Investment Takeaway

HCA’s long-term investment case is anchored in durable structural advantages: large-scale cost efficiency, high barriers to entry from capital and regulatory requirements, and an integrated care delivery ecosystem that supports referral and revenue capture across inpatient and outpatient settings. The investment outcome depends on maintaining operating discipline through reimbursement and labor cycles while managing the capital intensity required to sustain clinical capacity and technology investments.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for HCA.

businesswire.com2026-06-08

Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting

WALTHAM, Mass.--(BUSINESS WIRE)-- #HCA--Vizgen, Inc., a leader in spatial multiomics and developer of the MERSCOPE Ultra™ Platform, today announced it will debut a 3D Volumetric Tissue Mapping dataset in neurodegenerative brain tissue using MERFISH 2.0™ chemistry on the MERSCOPE Ultra Platform at the Human Cell Atlas (HCA) General Meeting, June 16-18, in Boston. The company will also launch Volumetric Tissue Mapping services and a new Cell Atlasing Hub, a central resource for the cell atlasing communi.

seekingalpha.com2026-06-08

Top 50 High-Quality Dividend Growth Stocks For June 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

fool.com2026-06-02

3 Beaten-Down Stocks to Buy and Hold Forever

Don't wait too long to buy the dip on these stocks.

zacks.com2026-05-28

HCA Healthcare to Acquire CHCP to Strengthen Workforce Development

HCA plans to acquire CHCP, expanding healthcare education efforts and boosting its pipeline of trained professionals across hospitals and care sites.

businesswire.com2026-05-27

HCA Healthcare Announces Agreement to Acquire The College of Health Care Professions

NASHVILLE, Tenn. & HOUSTON--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, and The College of Health Care Professions (CHCP), one of the largest allied healthcare training providers in Texas, today announced an agreement for HCA Healthcare to acquire ownership of CHCP. CHCP provides healthcare education to more than 8,000 students annually across 10 campuses throughout Texas and online. “The College of Health Care Professions has built a stro.

gurufocus.com2026-05-27

Is HCA Undervalued? DCF Says Worth $765

On May 27, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company currently facing a challenging price performance with a year-to-date dec

seekingalpha.com2026-05-20

HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

businesswire.com2026-05-19

HCA Healthcare Colleagues Volunteer More Than 41,800 Hours During Annual Days of Service Initiative

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced the results of its seventh annual We Show Up for Our Communities days of service volunteer initiative. In alignment with National Volunteer Month, HCA Healthcare colleagues across the country donated their time and expertise to help improve the health and well-being of the communities the company serves. “Caring for our communities is at the heart of HCA Healthca.

gurufocus.com2026-05-19

HCA DCF Analysis: Intrinsic Value $765 vs Price $423

On May 19, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company that has experienced a price performance of -0.8% over the past week, -1

gurufocus.com2026-05-08

HCA DCF Analysis: Intrinsic Value $765 vs Price $429

On May 08, 2026, we delve into the DCF analysis for HCA Healthcare Inc (HCA), a company that has seen varied price performance recently. Over the past week, the

businesswire.com2026-04-30

HCA Healthcare, Inc. to Present at May Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference: May 20, 2026, at 11:30am ET at the RBC Global Healthcare Conference A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or the Invest.

zacks.com2026-04-30

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

defenseworld.net2026-04-29

Comerica Bank Sells 3,248 Shares of HCA Healthcare, Inc. $HCA

Comerica Bank reduced its position in shares of HCA Healthcare, Inc. (NYSE: HCA) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,860 shares of the company's stock after selling 3,248 shares during the period. Comerica Bank's holdings in

gurufocus.com2026-04-27

HCA Healthcare Inc (HCA) Shares Surge 3.1% -- What GF Score of 97 Tells Investors

On April 27, 2026, HCA Healthcare Inc (HCA) shares rose 3.1% today, bringing the current price to $445.77. Over the past year, the stock has experienced a notab

businesswire.com2026-04-27

HCA Healthcare Names Cynthia Cifuentes-Finkel Senior Vice President of Marketing and Corporate Affairs

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare (NYSE: HCA) today announced that Cynthia Cifuentes-Finkel has been named senior vice president of marketing and corporate affairs, effective June 8, 2026. She will report to Mike McAlevey, executive vice president, chief legal and administrative officer, and will lead enterprise marketing, corporate communications, and stakeholder engagement in support of HCA Healthcare's enterprise growth priorities. “Cynthia is a strategic and accomplished lea.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Headlines (HCA, 2026-03-31 / Q1): Revenue $19.109B and Net Income $1.620B (EPS $7.15). QoQ, revenue fell from $19.513B (Q4) to $19.109B (-2.1%) while net income declined from $1.878B (-13.8%). YoY, Q1 revenue is essentially flat vs $18.605B in Q2 2025 (+2.7% on the nearest comparable quarter provided), and net income is down vs $1.653B (+0?; nearest comparable shows -2.0% vs 2025-06-30 and +0? vs 2025-09-30; using only provided indices 1–3 for YoY/QoQ the clearest is EPS: $7.15 vs $6.91 in 2025-06-30, +3.5%). Margins: net margin compressed to 8.48% from 9.62% in Q4 2025 and from 8.88% in Q2 2025, indicating profitability contraction. Cash flow: Operating cash flow was $2.014B and free cash flow $0.895B, with capex at -$1.119B. The company continued shareholder returns via buybacks (-$1.571B) and dividends (-$183M). Balance sheet: total assets rose to $61.45B from $60.72B, while leverage remains high with total debt ~$49.85B; however, interest coverage remains ~4.9x (Q1), suggesting manageable debt servicing. Shareholder returns: price is $488 with +47.43% 1-year change, well above the >20% momentum threshold. Analyst sentiment/valuation: consensus target $527.45 implies modest upside vs current price."

Revenue Growth

Neutral

Q1 revenue $19.109B vs Q4 $19.513B is -2.1% QoQ; sequentially it’s below recent levels, while the provided YoY-comparable quarter shows only low single-digit change.

Profitability

Neutral

Net income $1.620B is -13.8% QoQ and net margin fell to 8.48% from 9.62% (Q4). Margins are contracting over the latest 4-quarter window.

Cash Flow Quality

Positive

Q1 operating cash flow $2.014B and free cash flow $0.895B supported capital spending and meaningful shareholder returns (buybacks -$1.571B; dividends -$183M).

Leverage & Balance Sheet

Neutral

High leverage persists (total debt ~$49.85B; equity is negative). Liquidity ratios remain below 1, but interest coverage (~4.9x) indicates debt service remains workable.

Shareholder Returns

Strong

Strong total return profile driven by capital appreciation: stock up +47.43% over 1 year (momentum >20% threshold). Continued buybacks and dividends further support shareholder returns.

Analyst Sentiment & Valuation

Positive

Consensus target $527.45 vs $488 current price indicates modest upside; valuation appears supported by cash generation though price multiples remain elevated.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

HCA Q1 2026 showed solid topline and per-share growth (revenue +4.3%, adjusted EBITDA +~2%, adjusted EPS +~11%) but a margin step-down as costs did not flex quickly enough during a milder respiratory season and a January winter storm. Management quantified a ~$180M adjusted EBITDA headwind from delayed seasonal cost reduction plus the storm’s volume disruption, partially offset by Medicaid supplemental program strength. Medicaid DPP net benefits significantly beat expectations: Q1 realized about $200M versus expected $80M (and ~$120M above internal expectations). Despite the Q1 volatility, HCA reaffirmed full-year guidance ranges, adjusting the DPP assumption to a $50M to $250M decline for 2026 (excluding incremental future grandfathered approvals). Exchange dynamics remain a key driver: management reiterated $600M to $900M full-year adjusted EBITDA impact and highlighted payer mix/denial risk, while AI-driven operational programs and network expansion continue to support longer-run resiliency.

AI IconGrowth Catalysts

  • Digital transformation/AI rollout to more facilities, including ambient listening, documentation, nurse handoff program, and case management improvements driving better length-of-stay outcomes
  • Network expansion: >4% sites of care, ~1% hospital beds via capital spending, and +4% emergency room capacity
  • Improved quality and patient satisfaction metrics alongside reductions in average length of stay

Business Development

  • Medicaid state supplemental program approvals (Georgia grandfathered approval; Atlas reinstatement in Texas; Tennessee program referenced as prior-period benefit)
  • Reaffirmed focus on strategic payer partnerships (names not disclosed) emphasizing digital integration/admin simplification to reduce faxes/paper and improve dispute management

AI IconFinancial Highlights

  • Revenue +4.3% YoY; adjusted EBITDA +~2% YoY; diluted EPS (adjusted) +~11% YoY
  • Adjusted EBITDA margin -50 bps YoY (quarterly) driven by higher other operating expenses as a % of revenue (+90 bps) despite improvements in salaries/benefits (+30 bps) and supplies (+20 bps)
  • Seasonality/weather headwinds: milder respiratory season reduced respiratory admissions by 42% and respiratory ER visits by 32% vs last year; management quantified quarterly drag as +70 bps on admissions growth and +140 bps on ER growth
  • January winter storm impact: ~30 bps reduction in admissions growth and ~50 bps reduction in ER growth; combined adverse adjusted EBITDA impact estimated at ~$180 million
  • Medicaid DPP net benefits outperformance: Q1 net benefits realized ~+$200 million vs expected +$80 million (about +$120 million vs internal expectations); full-year DPP assumption updated to decline of $50M to $250M vs prior-year (excluding incremental impacts from any additional grandfathered approvals)
  • Exchange-related adjusted EBITDA impact estimated ~$150 million in Q1 2026 vs prior year; full-year expected range reiterated at $600M to $900M

AI IconCapital Funding

  • Capital expenditures: $1.1 billion in the quarter
  • Share repurchases: $1.57 billion of outstanding shares purchased in the quarter
  • Dividends: $183 million paid in the quarter
  • Cash flow from operations: $2.0 billion (22% increase vs Q1 2025)
  • Debt-to-adjusted EBITDA leverage: lower half of stated target range (exact level not disclosed)

AI IconStrategy & Ops

  • Broad resiliency plan ($400 million referenced by management in Q&A) progressing; first quarter lost some operating leverage due to temporal volume headwinds, but leverage improved as volumes recovered through February/March
  • Winter storm/seasonality: cost flex-down delayed because the respiratory season ended abruptly; operational costs normalized by March
  • Exchange environment tracking: same-facility exchange equivalent adjusted admissions declined ~15% YoY; same-facility uninsured equivalent admissions increased ~16% YoY (over half from exchange-to-uninsured movement; remainder from slower Medicaid application conversions)

AI IconMarket Outlook

  • 2026 guidance ranges reaffirmed; management stated Q1 outcomes are in line with original guidance assumptions provided 90 days earlier (despite respiratory dynamic)
  • Full-year volume assumption reiterated: ~2% to 3% volume growth (quarter was at the lower end of range)
  • Full-year exchange impact reiterated: $600 million to $900 million adjusted EBITDA
  • Florida DPP expectation: management feels positive on approval; program covers October 1, 2024 through September 30, 2025

AI IconRisks & Headwinds

  • Temporal respiratory season disruption: respiratory-related admissions down 42% and respiratory-related ER visits down 32% vs prior-year quarter; winter storm compounded weakness in January
  • Medicaid supplemental programs remain approval/timing dependent: Florida review delays create market uncertainty; management noted potential additional impacts not included in updated guidance
  • Exchange reform remains dynamic: management estimated exchange decline of 15% to 20% volume impact and reiterated it is reasonable, but acknowledged continued learning as grace-period behaviors mature
  • Denials/underpayments: payers increasing denial and underpayment activity across products; Medicare Advantage called out as a specific driver; recoveries mitigated earnings impact but levels remain high
  • Hurricane-impacted markets (especially Western North Carolina): labor/workforce deficit increases cost to serve higher demand; payer mix disruption worsens bottom-line outcomes

Q&A: Analyst Interest

  • EBITDA bridge to guidance: Management explained the Q1 miss vs internal expectations as a temporal respiratory season/winter storm cost-flex delay (~$180M adjusted EBITDA headwind) partially offset by stronger-than-modeled Medicaid DPP net benefits (+~$120M vs expected; Q1 realized ~$200M). They kept full-year guidance unchanged because offsetting factors are not structural.
  • AI/resiliency and cost outlook confidence: Management reaffirmed the $400M resiliency program trajectory, stating first-quarter leverage was muted by volume shortfalls but normalized by March. They described AI initiatives (ambient listening/documentation, physician productivity, nurse handoff rollout) and cited case management outcomes improving length of stay.
  • ACA/exchange mechanics and collections/bad debt: Analysts asked about Medicaid conversion slowdown and exchange grace-period treatment. Management said models assumed patient shifts (silver→bronze; increased within-silver benefits) and exchange-to-uninsured migration (~15% Q1). They also noted limited standardized eligibility/premium verification at point of service across exchange payers, affecting certainty of collections timing.

Sentiment: MIXED

Note: This summary was synthesized by AI from the HCA Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for HCA.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (HCA)

© 2026 Stock Market Info — HCA Healthcare, Inc. (HCA) Financial Profile